Christopher Rowan, MD
Cardiovascular Disease · Reno, NVNPI 1477783264
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,650 of the $48,325 with a category attached, or 80.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 63.5% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $14,679 and has fallen 93.4% since, to $974 in 2025. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $170.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31K
- AstraZeneca$12K
- Abbott$2K
- Novartis$620
- United Therapeutics Corporation$508
- Actelion Pharmaceuticals US, Inc.$446
- plus $3K from 28 others
Across 37 payments — averaging $6250.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$175K
- Daiichi Sankyo Inc.$26K
- Amgen$24K
- E.r. Squibb & Sons, L.L.C.$7K
What the payments were for
- Speaking & faculty fees$38,65080%
- Travel & lodging$2,0044%
- Food & beverage$7,53016%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 53 | $30,695 |
| AstraZeneca | 29 | $11,610 |
| Abbott | 22 | $1,645 |
| Novartis | 37 | $620 |
| United Therapeutics Corporation | 21 | $508 |
| Actelion Pharmaceuticals US, Inc. | 18 | $446 |
| Bayer | 11 | $224 |
| Medtronic | 6 | $209 |
| Scpharmaceuticals Inc. | 8 | $207 |
| Philips North America LLC | 5 | $197 |
| Merck | 8 | $188 |
| Sanofi-aventis U.S. LLC | 2 | $186 |
| Amgen | 8 | $168 |
| Johnson & Johnson(2 entities) | 9 | $153 |
| Pfizer | 4 | $153 |
| Abiomed | 6 | $147 |
| Edwards Lifesciences | 1 | $119 |
| Lexicon Pharmaceuticals, Inc. | 5 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $102 |
| Boehringer Ingelheim | 4 | $91 |
| Boston Scientific | 3 | $90 |
| Novo Nordisk | 4 | $85 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Shockwave Medical, Inc | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $32 |
| Biotronik Inc. | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $25 |
| Atricure, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$29,195
- FARXIGA$11,356
- ACCENT$995
- HeartMate 3 Left Ventricular Assist Device$189
- PRALUENT$120
- SAPIEN 3 Ultra RESILIA$119
- Mitra Clip system$113
How this compares
$48,325 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 17 | $341,670 |
| EliquisApixaban | 289 | $246,917 |
| OpsumitMacitentan | 14 | $176,366 |
| XareltoRivaroxaban | 159 | $149,152 |
| EntrestoSacubitril/Valsartan | 56 | $63,951 |
| FarxigaDapagliflozin Propanediol | 89 | $61,361 |
| Tadalafil | 23 | $52,734 |
| JardianceEmpagliflozin | 51 | $42,791 |
| Repatha SyringeEvolocumab | 24 | $24,974 |
| Repatha SureclickEvolocumab | 36 | $24,825 |
| Praluent PenAlirocumab | 15 | $13,131 |
| Atorvastatin Calcium | 356 | $4,164 |
| Flecainide Acetate | 113 | $3,990 |
| Spironolactone | 506 | $3,641 |
| Ezetimibe | 104 | $3,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $153 | $246,917289 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $446 | $176,36614 claims |
| Johnson & JohnsonXarelto | $153 | $149,152159 claims |
| NovartisEntresto | $620 | $63,95156 claims |
| AstraZenecaFarxiga | $11,610 | $61,36189 claims |
| Boehringer IngelheimJardiance | $91 | $42,79151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Reno
- Thomas-Duythuc ToReno$339K
- Jay MasonReno$227K
- Joseph StevensonReno$222K
- Devang DesaiReno$206K
- Ram ChallapalliReno$18K
- Anita KediaReno$9K
- Sridevi ChallapalliReno$8K
- Christopher WilsonReno$7K
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.